Clinical trial NCT04930861: Study of Codivir in Patients With COVID-19
Official title: Phase 1 Clinical Study of Codivir in Outpatients With COVID-19
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Covid19
Keywords: Corona
Coronavirus
COVID-19
SARS-CoV-2
Lead sponsor: Code Pharma
Sponsor class: INDUSTRY
First posted: 2021-06-18
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: This is an open label study to evaluate the safety and preliminary efficacy of Codivir in 12 mild or moderate COVID-19 patients and onset of symptoms within 72h prior to their inclusion. Treatment will begin in the hospital, participants will be discharged at Day 4 and continue the treatment up to Day 10 at home.
Primary purpose: TREATMENT

Brief summary: This is an open-label study to evaluate the safety and preliminary efficacy of Codivir in 12 mild or moderate COVID-19 patients and onset of symptoms within 72h prior to their inclusion. Treatment will begin in the hospital, participants will be discharged at Day 4 and continue the treatment up to Day 10 at home and followed up to day 28.

Detailed description: Eligible participants who agree to participate will be submitted to safety assessments, an RT-PCR and a quick test for COVID-19. Everyone will receive the treatments indicated for their case, except for other investigational medications. Codivir will be administered in addition to these treatments at a dose of 20 mg SC twice daily for 10 days. Participants will remain hospitalized for the first 3 days.

If they have progressed well, they will continue the treatment up to Day 10 at home, receiving a nurse's home visit twice a day to administer Codivir and collect vital signs. Participants will be followed up to Day 28 by telemedicine. A doctor will call them periodically to monitor the clinical evolution, collect adverse events, concomitant medication and instruct the participants. In case of unfavorable evolution, the participants will remain hospitalized receiving the appropriate care. The investigator will decide whether or not the investigational medication will continue, considering the participant's health and well-being.

Eligibility criteria: Inclusion Criteria:

1. Age between 18 and 60 years;
2. Male or female;
3. SARS-CoV-2 infection indicated by rapid test and confirmed by RT-PCR.
4. Mild or moderate COVID-19:

   * The oxygen saturation in room air \>93%;
   * \<30 breaths per minute;
5. No signs of hemodynamic decompensation.
6. Absence of pregnancy in women of childbearing age.
7. Able to understand and comply with the requirements of the protocol.
8. Consent to participate

Exclusion Criteria:

1. Participants in need of O2 supplementation by catheter or mask, invasive mechanical ventilation, or vasopressors.
2. Onset of symptoms or rapid test or positive RT-PCR for more than 72 hours of inclusion.
3. Participants in use or expected to use within 24 hours prior to the inclusion of drugs that are under clinical investigation as a therapeutic option for the treatment of COVID-19 (eg hydroxychloroquine, chloroquine, ivermectin, nitazoxanide, among others) during the study period;
4. Body mass index less than 19.9 or greater than 35;
5. Comorbidities such as: other serious infections, active malignancies, autoimmune diseases, liver, kidney or heart failure; another systemic disease and / or laboratory abnormality, which, in the investigator's opinion, prevent the patient from participating in the study;
6. Concomitant HIV, HBV or HCV infection.
7. Pregnancy or lactation;
8. Participation in another clinical trial in the 12 months preceding inclusion;
9. Anti-COVID-19 vaccination at any time;
10. Vaccination for any other infection in the 4 weeks prior to inclusion;
11. Any condition that increases the risk of participating in the study, in the opinion of the investigator.

Primary outcomes:
measure: Incidence and severity of adverse events related to the investigational product.
timeFrame: 28 days
Secondary outcomes:
measure: Clinical evolution according to the score of the World Health Organization between admission and days 10 and 28.
timeFrame: up to 28 days
measure: Clinical evolution according to NEWS2 score between admission and days 10 and 28.
timeFrame: up to 28 days
measure: RT-PCR negative.
timeFrame: up to 28 days
measure: Evolution of IgM & IgG Anti-SARS-CoV-2.
timeFrame: up to 28 days
Other outcomes:
Locations:
city: Campinas
country: Brazil
facility: Hospital Vera Cruz S A (Campinas-SP)
state: State Of São Paulo
Study officials:
affiliation: Code Pharma
name: Eynat Finkelshtein
role: STUDY_DIRECTOR
References: